DMU-2105, a CYP1B1 inhibitor, is primarily researched for its potential in cancer therapy. It targets the CYP1B1 enzyme, which is often overexpressed in various cancer cells. By inhibiting this enzyme, DMU-2105 may help reduce the production of carcinogenic metabolites and enhance the efficacy of certain chemotherapeutic agents. This compound is also being studied for its role in preventing drug resistance in cancer treatments, making it a promising candidate for combination therapies. Additionally, its application extends to research in understanding the role of CYP1B1 in other diseases where this enzyme plays a significant role.